by John Norman | Sep 21, 2021 | News
Optibrium appoints Professor Andy Black as non-executive Chair Appointment brings extensive pharmaceutical services and Board experience to drive commercial growth and development of new products to improve speed, efficiency, and productivity of drug discovery ... by John Norman | Sep 9, 2021 | News
Optibrium Releases 3D Ligand-based Design Modulefor StarDrop Drug Discovery Software Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data. CAMBRIDGE, UK, 9 September 2021 – Optibrium Limited, a developer of... by Alex Duarte | Jun 29, 2021 | News
Optibrium Publishes Major Peer-Reviewed Studyon AI Applications to Global Pharma Data Published in AI Letters, the study collaborators Optibrium, Takeda and Intellegens, demonstrated the application of deep learning imputation to a global pharma dataset, offering new... by Alex Duarte | May 20, 2021 | News
Optibrium and BioPharmics Enter Partnership on Computational Drug Design Industry-leading 3D ligand-based design approaches from BioPharmics will be available in StarDrop, Optibrium’s small molecule design and optimisation software. CAMBRIDGE, UK, 20 May 2021 –... by John Norman | Feb 23, 2021 | News
Optibrium appoints Dr Rae Lawrence as Director of Software Development • New role will drive development of AI-based drug discovery software solutions and lead development team expansion CAMBRIDGE, UK, 8 February 2021 – Optibrium™, a developer of software for... by John Norman | Feb 8, 2021 | News
Optibrium Raises Investment to Advance Computer-Aided Drug Discovery • Investment by Kester Capital will drive commercial growth and the development of new products to improve speed, efficiency, and productivity of the discovery process CAMBRIDGE, UK, 8...
Recent Comments